Unlock the Future of Lung Cancer Detection with BioAffinity - Company Overview
Jun. 20, 2024
bioAffinity Technologies addresses the urgent need for noninvasive, accurate earlystage cancer diagnosis and broad-spectrum cancer treatments. Lung cancer is the
leading cause of cancer-related deaths. The Company’s first product, CyPath®
Lung, improves early-stage detection of lung cancer, leading to increased survival,
fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical
costs. CyPath® Lung, a laboratory developed test (LTD), is patient-friendly and
physician focused. Physicians order CyPath® Lung for their patients after lung
cancer screening reveals a suspicious finding.
Patients collect their sample at home and ship overnight in a pre-paid envelope to
the Company’s commercial laboratory, Precision Pathology Laboratory Services,
where data is collected using flow cytometry. Proprietary automated data analysis,
developed using artificial intelligence (AI), detects lung cancer by analyzing the lung
microenvironment to identify cell populations that indicate malignancy. CyPath®
Lung has shown high sensitivity (92%), high specificity (87%) and high accuracy
(88%) in detecting early-stage lung cancer in patients with small pulmonary nodules
less than 20 millimeters. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at Precision Pathology and The
University of Texas at San Antonio.
bioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity, and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US Department of Defense’s purchase of tests
for ongoing research, the Company is well-poised for growth. The lung cancer diagnostics market is projected to reach $4.7 billion by 2030. The Company’s flow cytometry platform, enhanced by AI-driven automated data analysis, is being developed to aid in noninvasive diagnosis of COPD and asthma, which have a combined global market expected to reach $8.2 billion by 2027. The Company holds extensive U.S. and international patents. Insiders show strong support for the
Company with ownership at 35%. With a highly experienced leadership team, bioAffinity Technologies is well-positioned to drive innovation in early-stage cancer diagnosis and treatment.
